uniQure N.V. is a gene therapy company based in Amsterdam, Netherlands. The company is focused on the development of gene therapies for patients with genetic and acquired diseases. uniQure's lead product candidate, etranacogene dezaparvovec, is a gene therapy for the treatment of hemophilia B. The company was founded in 1998 and went public in 2014.